Moderna Aces COVID-19 Vaccine Results With 94.5% Efficacy

Outperforms Pfizer At First Analysis

Moderna’s stunning interim results add to the world’s relief brought by Pfizer’s first read-out, and also provide the US biotech with the commercial platform it needed

Moderna_Pills_Syringe
Moderna now looks set to join Pfizer/BioNTech in gaining emergency use authorization before the end of 2020.

Moderna’s COVID-19 vaccine candidate MRNA-1273 has produced a 94.5% level of efficacy in the first interim analysis of 95 cases from its Phase III COVE trial.

The results have provided more cheer in the fight against the pandemic and are also a boon for the company's...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip